Project Grant R21AR083065

Award Date 9/1/23
Completion Date 8/31/25
Dollars Obligated $409K
Federal Grant Program
93.846
Assistance Type
Project Grant
Place of Performance
San Francisco, CA 94143, USA
Similar Awards
This three-year, $906,000 project grant from the National Institutes of Health's National Institute of Arthritis and Musculoskeletal and Skin Diseases will fund research into obesity-promoting protein malonylation and its role in chondrocyte metabolic dysfunction and osteoarthritis development. Specifically, the grantee - Ohio University - will investigate how obesity accelerates osteoarthritis through "carbon stress," which causes metabolic byproducts to accumulate in cartilage...
This Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) aims to define the systemic mechanisms by which adipose (fat) tissue communicates with the knee joint to drive the development of osteoarthritis (OA). The $1,476,001 award to the Regents of the University of California, San Francisco will fund a comprehensive investigation of three potential interorgan crosstalk pathways: signaling through...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $667,125 to the University of Massachusetts Medical School (UMass Medical) to develop a long-lasting, bone-targeted gene therapy for treating osteogenesis imperfecta (OI), the most common bone fragility disease. The project aims to enhance bone-forming signaling pathways in OI patients by...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), will support research into the molecular regulatory mechanisms of a cartilage-enriched G protein-coupled receptor (GPCR) named ADGRG6 in maintaining joint homeostasis and preventing osteoarthritis (OA). The $426,889 award, effective from April 10, 2025 to March 31, 2030, will enable the University...
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $361,300 Project Grant under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to the University of North Carolina at Chapel Hill. The goal of this 2-year exploratory/developmental project is to use high-throughput small molecule screening and CRISPR screening technologies to identify signaling pathways and therapeutic targets for disease modification in osteoarthritis...
This $222,500 Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), will support research at The Children's Hospital of Philadelphia (CHOP) to investigate the pathogenic mechanisms of temporomandibular joint (TMJ) osteophyte formation. The key objectives are to test whether conditional ablation of the gene EXT1, which is involved in heparan sulfate synthesis, causes osteophyte formation...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), will support research focused on developing a cellular therapy approach to treat osteogenesis imperfecta (OI), a genetic disease that causes bone fragility. The $386,481 award to the University of Connecticut Health Center (UCHC) will fund a 5-year research project to evaluate different cell...
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded Vanderbilt University a $393,412 Project Grant (CFDA 93.846 - Arthritis, Musculoskeletal and Skin Diseases Research) to develop engineered cells as agents for treating osteoarthritis. The project aims to leverage advanced cell design platforms to create synthetic receptor-controlled, joint-resident cells that can detect cartilage degeneration and then upregulate the expression of transgenes to promote...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), will support research to determine the role of the mechanosensitive protein PIEZO1 in joint homeostasis and osteoarthritis (OA) susceptibility. The $691,089 award, effective July 15, 2025 through June 30, 2030, will fund studies at the University of Utah to: 1) identify how mutations in PIEZO1...
The National Institute of Dental and Craniofacial Research (NIDCR) awarded a $143,285 project grant under the Oral Diseases and Disorders Research program (CFDA 93.121) to the University of Southern California (USC). The project aims to identify the cellular origins of cartilage regeneration in the zebrafish jaw joint, which could inform future treatments for temporomandibular joint osteoarthritis (TMJ OA) in humans. The grant will fund research to optimize a transgenic cartilage ablation...

OSTEOCYTE-DEPENDENT MECHANISMS OF BONE CARTILAGE CROSSTALK IN OSTEOARTHRITIS - SUMMARY CARTILAGE AND SUBCHONDRAL BONE COOPERATE TO SUPPORT HEALTHY JOINT FUNCTION, AND DAMAGE TO EITHER CONTRIBUTES TO OSTEOARTHRITIS AND PAIN. NONETHELESS, THE MECHANISMS BY WHICH THIS COOPERATION BETWEEN CARTILAGE AND BONE OCCURS REMAIN UNCLEAR. PRELIMINARY AND PUBLISHED DATA SUPPORT THE DIAGNOSTIC AND CLINICAL IMPORTANCE OF SUBCHONDRAL BONE SHAPE IN OSTEOARTHRITIS (OA) PROGRESSION AND PAIN. BONE SHAPE FEATURES, IDENTIFIED BY DEEP LEARNING ALGORITHMS, ARE AMONG THE STRONGEST PREDICTIVE BIOMARKERS FOR OA. HOWEVER, A MAJOR GAP IN UNDERSTANDING REMAINS IDENTIFICATION OF THE CELLAR AND MOLECULAR MECHANISMS CONTROLLING JOINT SHAPE. DEFINING THESE MECHANISMS COULD REVEAL PREVENTATIVE OR THERAPEUTIC STRATEGIES TO PROTECT JOINTS FROM OA. THIS TEAM DESCRIBED A NEW AND CAUSAL ROLE FOR OSTEOCYTES IN OA, SUCH THAT LOSS OF SUBCHONDRAL BONE OSTEOCYTE FUNCTION CAUSES CARTILAGE DEGENERATION AND JOINT SHAPE CHANGE. THEREFORE, WITH EXPERTISE IN OSTEOCYTE BIOLOGY, DEEP LEARNING, AND STATISTICAL GENETICS, THIS TEAM TAKES AN INNOVATIVE, MULTI-DIMENSIONAL APPROACH TO IDENTIFY THESE MECHANISMS, AS WELL AS GENETIC AND IMAGING BIOMARKERS THAT CAN BE USED TO DIAGNOSE EARLY-STAGE OA WHEN THE DISEASE CAN STILL BE THERAPEUTICALLY MODIFIED. THIS PROJECT WILL TEST THE HYPOTHESIS THAT MRI AND GENETIC MARKERS OF JOINT SHAPE CAN IDENTIFY INDIVIDUALS AT HIGH RISK OF OA, AND THAT AGENTS TARGETING OSTEOCYTES CAN PREVENT JOINT SHAPE CHANGES TO MITIGATE OA. AIM 1 WILL EXTRACT GENETIC FACTORS ASSOCIATED WITH JOINT SHAPE TRAITS THAT PREDICT OA PROGRESSION AND JOINT PAIN IN THE HUMAN OSTEOARTHRITIS INITIATIVE (OAI) COHORT. THE FUNCTION OF THESE GENETIC FACTORS, INCLUDING A CANDIDATE OSTEOCYTE-DERIVED FACTOR THAT HAS THERAPEUTIC POTENTIAL IN CLINICAL STUDIES, WILL BE EXAMINED IN AIM 2. THIS PROJECT WILL IMPACT THE IDENTIFICATION OF GENETIC CORRELATES TO IMAGING TRAITS THAT PREDICT CLINICALLY RELEVANT OA OUTCOMES IN EARLY OA, SUGGEST BIOLOGICAL MECHANISMS DRIVING JOINT SHAPE CHANGE, AND HIGHLIGHT THESE MECHANISMS AS POTENTIAL TARGETS FOR OA DIAGNOSTICS AND THERAPIES. THEREFORE, SUCCESSFUL COMPLETION OF THIS PROJECT COULD FILL A MAJOR CLINICAL GAP BY DEVELOPING IMAGING AND GENETIC BIOMARKERS AND THERAPIES THAT CAN PRECISELY IDENTIFY AND TREAT SUBGROUPS OF PEOPLE AT HIGH RISK OF OA DUE TO JOINT SHAPE CHANGE EARLY ENOUGH TO PREVENT SEVERE JOINT DISEASE.

Posted 8/28/23